Posted by Michael Wonder on 23 Dec 2021
Allarity Therapeutics submits new drug application to the U.S. FDA for dovitinib for third-line treatment of renal cell carcinoma
22 December 2021 - New drug application is supported by Allarity’s previously-filed pre-market approval submission to the FDA for the Dovitinib DRP companion diagnostic to select renal cell carcinoma patients most likely to respond to the drug.
Allarity Therapeutics today announced the submission of a new drug application with the U.S. FDA seeking marketing approval for dovitinib for the third-line treatment of renal cell carcinoma patients.
